Elevance Health account plan
integrated whole health approach
At a glance
Elevance Health, an Indianapolis Blue Cross Blue Shield insurer, has about 45.2 million medical members and $197,584 million FY2025 revenue.
Elevance Health, headquartered in Indianapolis, is one of the largest U.S. health insurers by medical membership, with about 45.2 million medical members at December 31, 2025. It is the Blue Cross licensee in California and the Blue Cross and Blue Shield licensee in 13 other states, trading mainly as Anthem, and also sells under the Wellpoint, Carelon, MMM and Simply Healthcare brands. It earns risk-based premiums, administrative fees from self-funded employers, and pharmacy and health service fees through Carelon. FY2025 operating revenue was $197,584 million (+12.8%) and shareholders' net income $5,662 million (-5.3%); about 32% of revenue came from U.S. government agencies. It employed about 97,100 people at year-end 2025 (71,900 in the U.S., 25,200 international).
Business units
Health Benefits
about 70% of FY2025 segment revenue before eliminations ($167,094 million)Commercial, Individual ACA, fee-based employer services, Medicare Advantage, Medicare Supplement, Medicaid and the Federal Employee Program under the Anthem and Wellpoint brands. Operating gain fell 33.4% to $4,158 million in FY2025 on higher medical cost trends, and Q2 2026 margin was 2.1%. Led by Charles M. (Morgan) Kendrick (Commercial) and Felicia F. Norwood (Government).
CarelonRx
about 18% of FY2025 segment revenue before eliminations ($43,400 million)The pharmacy benefit manager: home delivery and specialty pharmacies, formulary management, pharmacy networks, rebate administration and infusion centers, serving affiliated plans and external clients. FY2025 operating gain rose 11.3% to $2,418 million; certain core services are delegated to CVS Health under an agreement running through December 31, 2027. Led by Peter D. Haytaian.
Carelon Services
about 12% of FY2025 segment revenue before eliminations ($28,316 million)Specialty utilization management, post-acute care including CareBridge, behavioral health, care navigation and primary care, plus Carelon Insights (payment integrity, HealthOS data exchange, analytics and business process services), often on risk-based contracts. Revenue grew 57.7% in FY2025 with CareBridge; operating gain was $960 million.
Corporate & Other
Businesses below segment thresholds, unallocated corporate expense and enterprise technology investments; it posted an operating loss of $337 million in FY2025.
Strategic priorities
- Lower cost and simpler navigation
- The CEO restated the strategy in April 2026 as to "lower the cost of healthcare and simplify how people navigate the system", with leadership realigned to tie Health Benefits more closely to Carelon.
- AI at scale
- Elevance is investing more than $1 billion in digital and AI-enabled capabilities: an AI virtual assistant used by 22 million commercial members, AI access for more than 60,000 associates, and Health OS in prior authorization with a goal of 80% real-time decisions.
- Operating Model Transformation Program
- A 2026-2027 programme to cut organisational layers, modernise IT platforms and use AI more widely, including targeted workforce reductions; $129 million of charges were booked in H1 2026.
- Fixing Medicaid and repositioning Medicare Advantage
- Medicaid margin is guided at about -1.75% for 2026, seen as the trough; Elevance is exiting the D.C. Medicaid market and expects more exits over the next 12 to 18 months. Medicare Advantage is refocused on D-SNP and HMO products and on track for at least a 2% operating margin in 2026.
- Scaling Carelon value-based solutions
- CareBridge was combined with care-at-home into one risk-based offer; the programmes have reduced hospital readmission by 20%, and aligned medical-pharmacy clients save upwards of $100 per member per month.
- Return to EPS growth in 2027
- Management targets at least 12% adjusted EPS growth in 2027 off a 2026 baseline of at least $26.
Latest results
In Q2 2026 operating revenue was $49,826 million (+0.8%), with premium rate increases and CarelonRx growth offset by membership attrition. Shareholders' net income fell 16.1% to $1,463 million and diluted EPS was $6.71 (adjusted $7.45); the benefit expense ratio rose to 89.7% on elevated Medicaid and Medicare cost trend, partly offset by better Individual ACA results. Medical membership was 44,949 thousand at June 30, 2026 (-1.5%), with Medicare Advantage down 15.9% after deliberate repositioning. Full-year 2026 guidance was raised to adjusted diluted EPS of at least $27.00, diluted EPS of at least $20.10 and operating cash flow of at least $6.0 billion. CMS confirmed on July 13, 2026 that the Medicare Advantage risk-adjustment matter is closed without sanctions.
Investments and deals
- Recent acquisitions
- Paragon Healthcare (infusion, March 2024), CareBridge (December 10, 2024) and Centers Plan for Healthy Living (New York managed long-term care, December 31, 2024); the life and disability business was sold April 1, 2024.
- Digital and AI investment
- More than $1 billion in digital and AI-enabled capabilities, including Sydney Health, which touches about 22 million members, and the Health OS provider connectivity platform.
- One-time second-half 2026 investments
- An approximately $0.80 per share below-the-line gain in Q2 2026 is being spent on one-time investments in medical cost management, member experience, provider connectivity, operating efficiency and Carelon.
- Capital returns
- In 2025 Elevance spent $2,605 million on buybacks, $1,529 million on dividends and $1,116 million on capex; six-month 2026 repurchases were $1,358 million and the quarterly dividend is $1.72.
- ACA market expansion
- ACA expansion into Florida, Maryland and Texas in 2025 and into Washington under Wellpoint in 2026.
Challenges and risks
- Elevated medical cost trend
- The FY2025 benefit expense ratio rose to 90.0% on higher cost trend in all lines; Medicaid pressure comes from behavioral health including ABA therapy, specialty pharmacy, outpatient surgery and emergency department use.
- Policy changes to Medicaid, ACA and PBMs
- Enhanced ACA premium tax credits expired December 31, 2025; OBBBA Medicaid work requirements and redeterminations phase in mostly in 2027-2028; the 2026 PBM reform requires rebate pass-through and Part D delinking from 2028.
- Membership attrition
- Medicaid fell to 8.5 million members in 2025 (-4.7%), and medical membership dropped 469 thousand in Q2 2026 on a commercial fee-based customer transition and ACA and Medicaid attrition.
- Government payment scrutiny
- CMS is scaling up RADV audits; a CMS risk-adjustment matter led to a $935 million accrual in Q1 2026 before it was closed.
- Provider friction and dependence on third parties
- The company names provider relations, data and cyber risk, AI use and its reliance on CVS for core pharmacy services among its risks.
What leadership says
“Our second quarter results exceeded our outlook, supported by disciplined execution and improved operating performance across our diversified portfolio.”
“we're investing more than $1 billion in digital and AI-enabled capabilities”
“In many cases, we've compressed months of work into days.”
“maniacally focused on affordability and simplicity”
Where a supplier can help
- AI and automation for administrative work
- Tied to the AI-at-scale priority and the Transformation Program: Elevance wants to automate administrative expense, simplify structures and modernise IT platforms.
- Provider connectivity and prior authorization
- Tied to the provider-friction challenge: the goal of 80% real-time prior authorization and fewer documentation requests and avoidable denials opens room for interoperability and clinical data tools.
- Medical cost management in Medicaid
- Tied to the medical cost challenge: behavioral health, specialty pharmacy and emergency department use are named cost drivers where analytics or care programmes could help.
- Member engagement and Stars
- Tied to the Medicare Advantage repositioning: Stars is a core priority, supported by AI-powered member engagement and clinical data interoperability.
- Employer affordability offers
- Tied to the commercial selling season: with a near-record National Accounts pipeline and employers focused on affordability, partners that strengthen integrated medical-pharmacy offers fit the sales motion.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Elevance Health?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Elevance Health Annual Report on Form 10-K, fiscal year ended December 31, 2025
- Elevance Health (Indianapolis; Indiana corporation) is one of the largest U.S. health insurers by medical membership: about 45.2 million medical members at December 31, 2025, an independent Blue Cross and Blue Shield licensee (Anthem Blue Cross / Anthem Blue Cross and Blue Shield) in California and 14 other states, plus the Wellpoint, Carelon, MMM and Simply Healthcare brands. About 97,100 employees (71,900 in the U.S., 25,200 international).
- FY2025: total operating revenue $197,584 million (+12.8%), shareholders' net income $5,662 million (-5.3%), diluted EPS $25.21 (-1.8%); benefit expense ratio 90.0% (+150 bp) on higher medical cost trend in all lines, "principally within our ACA business"; operating cash flow $4,290 million.
- Four reportable segments: Health Benefits ($167,094 million operating revenue, operating gain $4,158 million, -33.4%), CarelonRx ($43,400 million, gain $2,418 million, +11.3%), Carelon Services ($28,316 million, +57.7% with CareBridge, gain $960 million) and Corporate & Other.
- Membership mix: Employer Group fee-based 45.5% of medical members, Medicaid 18.8%, BlueCard 14.4%, Employer Group risk-based 8.0%, Medicare 6.9%. Medicaid fell to 8.5 million (-4.7%, redeterminations); Medicare Advantage grew to 2,230 thousand (+7.9%). About 32% of 2025 revenue came from U.S. government agencies.
- Cost pressure: Medicaid-to-ACA shifts and lower effectuation drove "a market-wide increase in morbidity"; Medicaid trend elevated on acuity and utilization; enhanced ACA premium tax credits expired December 31, 2025. Medicare Part D standalone plans are dropped in 2026.
- Regulation reshaping the book: the One Big Beautiful Bill Act (Medicaid work requirements and more frequent redeterminations, mostly 2027-2028), the February 2026 PBM reform (rebate pass-through to commercial sponsors, Part D delinking from 2028), stepped-up CMS RADV audits.
- Medicare Stars: about 40% of MA members in 4+ Star plans for payment year 2026, rising to about 59% for payment year 2027.
- Capital: $2,605 million of buybacks, $1,529 million dividends, $1,116 million capex in 2025; $6,695 million buyback authorization left; quarterly dividend $1.72; CarelonRx's CVS Caremark services agreement runs through December 31, 2027.
- Elevance Health Quarterly Report on Form 10-Q, quarter ended June 30, 2026
- Q2 2026 operating revenue $49,826 million (+0.8%); H1 $99,320 million (+1.2%), on premium rate increases and CarelonRx product revenue, offset by membership attrition.
- Q2 shareholders' net income $1,463 million (-16.1%), diluted EPS $6.71 (-13.1%); H1 EPS $14.73 (-15.0%). Benefit expense ratio 89.7% in Q2 (+80 bp), on elevated Medicaid and Medicare trend, partly offset by better Individual ACA.
- Segment Q2 operating gain: Health Benefits $896 million (-42.6%, margin 2.1%), CarelonRx $582 million (+8.6%), Carelon Services $366 million (-8.5%).
- Medical membership 44,949 thousand at June 30, 2026 (-1.5%): Medicare Advantage -15.9% to 1,897 thousand after "deliberate repositioning", Medicaid -4.3%, Employer Group risk-based -5.5%; Employer Group fee-based +1.7%.
- CMS risk-adjustment matter: $935 million accrued at March 31, $342 million paid May 27, $593 million left; CMS confirmed on July 13 that no sanctions will be imposed.
- New 2026-2027 Operating Model Transformation Program to cut layers and use AI more widely: $129 million of charges in H1, mostly severance.
- Operating cash flow H1 $6,245 million; buybacks $1,358 million; ACA expansion into Washington in 2026 under Wellpoint.
- Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance (earnings release, Exhibit 99.1)
- Q2 2026 operating revenue $49.8 billion (+0.8%); diluted EPS $6.71, adjusted diluted EPS $7.45, helped by an approximately $0.80 per share net below-the-line benefit.
- FY2026 guidance raised: diluted EPS at least $20.10, adjusted diluted EPS at least $27.00, operating cash flow at least $6.0 billion.
- CEO Gail Boudreaux: accelerating investment in "medical cost management, member experience, provider connectivity, operating efficiency, and Carelon’s value-based solutions", and confident of at least 12% adjusted EPS growth in 2027 off the 2026 baseline.
- Health Benefits: revenue $42.7 billion, operating gain $0.9 billion, margin 2.1% (3.8% a year earlier); medical membership about 44.9 million, down 469 thousand sequentially on a known commercial fee-based customer transition and ACA and Medicaid attrition.
- Carelon (CarelonRx plus Carelon Services): revenue $19.2 billion (+6%), operating gain $0.9 billion, margin 4.9%.
- Benefit expense ratio 89.7% (+80 bp); adjusted operating expense ratio 11.0% (+100 bp); days in claims payable 45.4.
- Capital: 0.7 million shares bought back for $234 million in Q2; quarterly dividend $1.72; about $5.3 billion of buyback authorization left.
- Q2 2026 Elevance Health earnings call (edited transcript)
- Guidance raised to at least $27 adjusted EPS for 2026; at least $26 is the baseline for "at least 12% adjusted EPS growth in 2027". The ~$0.80 below-the-line gain funds one-time H2 investments that will not recur in 2027.
- Investment priorities: earlier medical-cost trend detection ("compressed months of work into days"), Sydney Health and Concierge care (Sydney Health touches about 22 million members), Health OS provider connectivity (aiming at 80% real-time prior authorization), and scaling Carelon.
- Medicaid: full-year margin outlook about -1.75% unchanged, 2026 seen as the trough; agreed to exit the D.C. Medicaid market and expects to exit more markets "over the next 12 to 18 months"; July rate updates towards the upper end of mid-single digits.
- Medicare Advantage repositioning (D-SNP and HMO focus) is working: on track for at least a 2% operating margin in 2026; 2027 bids prioritise dual-eligible members.
- Individual ACA: expect at least 1 million members at end 2026; favourable 2025 risk adjustment largely re-reserved.
- Cost drivers in Medicaid: behavioral health including ABA therapy, specialty pharmacy, outpatient surgery and emergency department use.
- Commercial: 2026 was "a record year" in National Accounts, a 2027 pipeline almost as large, and clients that left are moving back to Anthem. CarelonRx off to a good 2027 selling season.
- Q1 2026 Elevance Health earnings call (edited transcript)
- Strategy restated by the CEO: "lower the cost of healthcare and simplify how people navigate the system"; leadership realigned to tie Health Benefits more closely to Carelon.
- Q1 2026 adjusted EPS $12.58; FY2026 guidance raised to at least $26.75, with about $1 per share of non-recurring investment income excluded from the $25.75 baseline for 2027 growth of at least 12%.
- CMS risk-adjustment matter: $935 million accrued; a $129 million business optimization charge for simplifying the organisation.
- AI: "more than $1 billion" invested in digital and AI-enabled capabilities; an AI virtual assistant used by 22 million commercial members; AI access for more than 60,000 associates; Health OS cutting denials by "almost 70%".
- Carelon: CareBridge combined with care-at-home into one risk-based offer; readmissions down 20% and more than 10% savings on post-acute care. Aligned medical and pharmacy clients save "upwards of $100 per member per month".
- Commercial: almost-record 2027 National Accounts pipeline, national renewal around 99.3%, roughly 2 million members in the pipeline; CarelonRx sales ahead of plan with two marquee national wins.
- Medicaid margin outlook about -1.75%, 2026 the trough; Medicare Advantage on track for at least 2% margin.
Questions about Elevance Health
What does Elevance Health do?
Elevance Health is a U.S. health insurer and Blue Cross Blue Shield licensee (mainly as Anthem) that also runs the CarelonRx pharmacy benefit manager and Carelon health services. Its companies serve approximately 104 million consumers.
What is Elevance Health's revenue?
FY2025 operating revenue was $197,584 million, up 12.8%, with shareholders' net income of $5,662 million. Q2 2026 operating revenue was $49,826 million.
How many employees does Elevance Health have?
About 97,100 at December 31, 2025: 71,900 in the U.S. and 25,200 internationally.
Who leads Elevance Health?
Gail K. Boudreaux has been President and CEO since November 2017; Mark B. Kaye is CFO.
What is Elevance Health's strategy?
To lower the cost of healthcare and simplify navigation, by tying Health Benefits closer to Carelon, using AI at scale, fixing Medicaid margins and repositioning Medicare Advantage, with a target of at least 12% adjusted EPS growth in 2027.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)